Bioactive glass S53P4 as bone graft substitute in treatment of osteomyelitis

Bone

Volumn 47, Issue 2, 2010, Pages 212-218

  Lindfors, N C ^a   Hyvonen P ^b   Nyyssonen M ^c   Kirjavainen, M ^a   Kankare, J ^a   Gullichsen, E ^d   Salo, J ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b OULU UNIVERSITY HOSPITAL   (Finland)

^c NORTH KARELIA CENTRAL HOSPITAL   (Finland)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Antibacterial; Bioactive glass; Bone substitute; Osteoconductive; Osteomyelitis

Indexed keywords

BIOMATERIAL; BIOACTIVE GLASS S53P4; BONE PROSTHESIS; GLASS;

ADOLESCENT; ADULT; AGED; ANTIBACTERIAL ACTIVITY; ARTICLE; BIOACTIVE GLASS S53P4; BONE GRAFT; BONE PROSTHESIS; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; FEMALE; HUMAN; MALE; MULTICENTER STUDY; MUSCLE FLAP; OSSIFICATION; OSTEOMYELITIS; POSTOPERATIVE COMPLICATION; PROSTHESIS INFECTION; STAPHYLOCOCCUS AUREUS; TRANSPLANTATION TOLERANCE; TREATMENT RESPONSE; WOUND INFECTION; BONE TRANSPLANTATION; CHEMISTRY; MICROBIOLOGY; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PATHOLOGY; PHYSIOLOGY; POSTOPERATIVE CARE; RADIOGRAPHY; SPINE; THERAPEUTIC USE; TIBIA; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BONE SUBSTITUTES; BONE TRANSPLANTATION; FEMALE; GLASS; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; OSTEOMYELITIS; POSTOPERATIVE CARE; SPINE; STAPHYLOCOCCUS AUREUS; TIBIA;

EID: 77955980806     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2010.05.030     Document Type: Article

References (36)

1. Lazzarini L., Mader J.T., Cahoun J.H. Osteomyelitis in long bones. J Bone Joint Surg 2004, 86-A:2305-2318.
2. Lew D.P., Waldfogel F.A. Osteomyelitis. Lancet 2004, 364:369-379.
3. Haartemann-Heurtier A., Senneville E. Diabetic foot osteomyelitis. Diabtes Metab 2008, 34:87-95.
4. Riise Ø.R., Kirhus E., Handeland K.S., FlatØ B., Reiseter T., Cvancarova M., Nakstad B., Wathne K.-O. Childhood osteomyelitis-incidence and differentiation from other acute onset musculoskeletal features in a population-based study. Pediatrics 2008, 8:45-55.
5. Konttinen Y.T., Tagaki M., Mandelin J., Lassus J., Salo J., Ainola M., Li T.F., Virtanen I., Liljeström M., Sakai H., Kobayashi Y., Sorsa T., Lappalainen R., Demulder A., Santavirta S. Acid attack and cathepsin K in bone resorption around total hip replacement prosthesis. J Bone Miner Res 2001, 16:1780-1786.
6. Powerski M., Maier B., Frank J., Marzi I. Treatment of severe osteitis after elastic intramedullary nailing of a radial bone shaft fracture by using cancellous bone graft in Masquelet technique in a 13-year-old adolescent girl. J Pediatr Surg 2009, 44:17-19.
7. Parsson B., Strauss E. Surgical management of chronic osteomyelitis. Am J Surg 2004, 188:57-66.
8. Andersson Ö.H., Kangasniemi I. Calcium phosphate formation at the surface of bioactive glass in vitro. J Biomed Mater Res 1991, 24:1019-1030.
9. Andersson Ö.H., Karlsson K.H., Kangasniemi K. Calcium phosphate formation at the surface of bioactive glass in vivo. J Non-Cryst Solids 1990, 119:290-296.
10. Hench L.L., Paschall H.A. Direct chemical bond of bioactive glass-ceramic materials to bone and muscle. J Biomed Mater Res Symp 1973, 4:25-42.
11. Hench L.L., Wilson J. Surface active biomaterials. Science 1984, 226:630-635.
12. Hench L.L. Bioactive ceramics. Ann N Y Acad Sci 1988, 523:54-71.
13. Lindfors N.C., Aho A.J. Granule size and composition of bioactive glass affect osteoconduction in rabbit. J Mater Sci Mater Med 2003, 14:265-372.
14. Leppäranta O., Vaahtio M., Peltola T., Zhang D., Hupa L., Hupa M., Ylänen H., Salonen J.I., Viljanen M.K., Eerola E. Antibacterial effect of bioactive glasses on clinically important anaerobic bacteria in vitro. J Mater Sci Mater Med 2008, 19:547-551.
15. Munukka E., Leppäranta O., Korkeamäki M., Vaahto M., Peltola T., Zhang D., Hupa L., Ylänen H., Salonen J.I., Viljanen M.K., Eerola E. Bactericidal effects of bioactive glasses on clinically important aerobic bacteria. J Mater Sci Mater Med 2008, 19:27-32.
16. Day R.M. Bioactive glass stimulates the secretion of angiogenetic growth factors and angiogenesis in vitro. Tissue Eng 2005, 11:768-777.
17. Stoor P., Söderling E., Grenman R. Interactions between the bioactive glass S53P4 and the atrophic rhinitis-associated microorganism Klebsiella ozaenae. J Biome Mater Res Appl Biomater 1999, 48:869-874.
18. Walenkamp G.H., Kleijn L.L., de Leeuw M. Osteomyelitis treated with gentamicin-PMMA beads: 100 patients followed for 1-12years. Acta Orthop Scand 1998, 69:518-522.
19. Boyd D., Towler M.R. The processing, mechanical properties and bioactivity of zinc based glass ionomer cements. J Mater Sci Mater Med 2005, 16:843-850.
20. Gitelis S., Brebach G.T. The treatment of chronic osteomyelitis with a biodegradable antibiotic-impregnated implant. J Orthop Surg 2002, 10:53-60.
21. Efstathopoulos N., Giamarellos-Bourboulis E., Kanellakopoulou K., Lazzarettos I., Giannoudis P., Frangia K., Magnissalis E., Papadaki M., Nikolaou V.S. Treatment of experimental osteomyelitis by methicillin resistant Staphylococcus aureus with bone cement system releasing grepafloxacin. Injury 2008, 39:1384-1390.
22. Zhang D., Munukka E., Leppäranta O., Hupa L., Ylänen H., Salonen J., Eerola E., Viljanen M.K., Hupa M. Comparison of antibacterial effect of three bioactive glasses. Key Eng Mat 2006, 309-311:345-348.
23. Stoor P., Söderling E., Salonen J.I. Antibacterial effects of a bioactive glass paste on oral microorganisms. Acta Odontol Scand 1998, 56:161-165.
24. Allan I., Newman H., Wilson M. Antibacterial activity of particulate Bioglass against supra- and subgingival bacteria. Biomaterials 2001, 22:1683-1687.
25. Wren A.W., Boyd D., Thornton R., Cooney J.C., Towler M.R. Antibacterial properties of a tri-sodium citrate modified glass polyalkenoate cement. J Biomed Mater Res Appl Biomater 2009, 90:700-709.
26. Zongping X., Xin L., Weitao J., Changqing Z., Wenhai H., Jianqiang W. Treatment of osteomyelitis and repair of bone defect by degradable bioactive borate glass releasing vancomycin. J Con Rel 2009, 139:118-126.
27. Banai S., Jaklitsch M.T., Shou M., Lazarous D.F., Scheinowitz M., Biro S., Epstein S.E., Unger E.F. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation 1994, 89:2183-2189.
28. Pearlman J.D., Hibberd M.G., Chuang M.L., Harada K., Lopez J.J., Gladstone S.R., Friedman M., Sellke F.W., Simons M. Magnetic resonance mapping demonstrates benefits of VGEF-induced myocardial angiogenesis. Nat Med 1995, 1:1985-1989.
29. Folkman J. Tumor angiogenesis. Adv Cancer Res 1985, 43:175-203.
30. Leu A., Leach L.K. Proangiogenic potential of a collagen/bioactive substrate. Phar Res 2008, 25:1222-1229.
31. Leach J.K., Kaigler D., Wang Z., Krebsbach P.H., Moonley D.J. Coating of VEGF-releasing scaffolds with bioactive glass for angiogenesis and bone regeneration. Biomaterials 2006, 27:3249-3255.
32. Peltola M.J., Aitasalo K.M.J., Suonpää J.T.K., Yli-Urpo A., Laippala P.J. In vivo model for frontal sinus and calvarian bone defect obliteration with bioactive glass S53P4 and hydroxyapatite. J Biomed Mater Res Appl Biomater 2001, 58:261-269.
33. Lindfors N.C., Heikkilä J.T., Koski I., Mattila K., Aho A. Bioactive glass and autogenous bone as bone graft substitutes in benign bone tumors. J Biomed Mater Res Appl Biomater 2009, 90:131-136.
34. Lindfors NC, Koski I, Heikkilä JT, Mattila K, Aho AJ. A prospective randomized 14-year follow-up study of bioactive glass and autogenous bone as bone graft substitutes in benign bone tumors. J Biomed Mater Res 2010;94:157-164.
35. Lindfors N.C. Treatment of a recurrent aneurysmal bone cyst with bioactive glass in a child allows for good remodelling and growth. Bone 2009, 45:398-400.
36. Lazzarini L., Lipsky B.A., Mader J.T. Antibiotic treatment of osteomyelitis: what have we learned form 30years of clinical trials?. Int J Inf Dis 2005, 9:127-138.